huahaipharm(SH:600521)2021-04-25 16:00Financial Performance - Net profit attributable to shareholders was CNY 255,087,177.63, an increase of 15.60% year-on-year[4] - Operating revenue for the period was CNY 1,496,853,661.87, down 4.69% from the same period last year[4] - Basic earnings per share increased by 20.00% to CNY 0.18[4] - The company reported a total comprehensive income for Q1 2021 of approximately ¥260.17 million, compared to ¥234.98 million in Q1 2020, marking an increase of 10.67%[22] - Net profit for Q1 2021 reached approximately ¥259.72 million, an increase of 11.85% from ¥232.31 million in Q1 2020[22] Cash Flow - Net cash flow from operating activities was CNY 64,672,579.69, a significant decrease of 81.79% compared to the previous year[4] - Cash inflows from operating activities amounted to CNY 1,707,458,758.68, up from CNY 1,506,061,450.73 in the same period last year, representing an increase of about 13.4%[25] - Cash outflows from investing activities totaled CNY 533,741,673.70, significantly higher than CNY 246,035,031.52 in Q1 2020, indicating increased investment activity[26] - The net cash flow from investing activities was -CNY 415,821,448.47, worsening from -CNY 232,826,937.81 in the previous year[26] - Cash inflows from financing activities were CNY 478,336,813.40, down from CNY 821,363,881.75 in Q1 2020, showing a decline of approximately 41.7%[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 12,945,125,162.25, a decrease of 0.35% compared to the end of the previous year[4] - Total current assets decreased to ¥6,110,788,987.74 from ¥6,523,111,548.32, with cash and cash equivalents dropping significantly[13] - Total liabilities decreased from ¥6,266,663,758.42 to ¥5,966,770,100.55, a reduction of approximately 4.8%[19] - Total equity increased from ¥6,724,102,583.55 to ¥6,978,355,061.70, reflecting a growth of about 3.8%[19] - Current liabilities decreased to ¥2,572,201,564.43 from ¥2,890,933,074.54, indicating improved liquidity management[14] Research and Development - R&D expenses increased by 32% to ¥153,202,310.66 compared to ¥115,972,351.02 in the same period last year, primarily due to an increase in biological drug R&D projects[10] - Research and development expenses increased to approximately ¥153.20 million in Q1 2021, up 32.06% from ¥115.97 million in Q1 2020[21] Investment and Financial Activities - The company reported a non-operating income of CNY 104,996,876.22, primarily from non-current asset disposal gains[5] - Investment income rose significantly by 1497% to ¥100,462,031.26, mainly from the sale of equity in Hangzhou Duoxi Biotechnology Co., Ltd.[10] - Financial expenses surged by 428% to ¥28,220,060.84, attributed to increased foreign exchange losses from USD fluctuations[10] Shareholder Information - The number of shareholders at the end of the reporting period was 45,054[6] - The company reported a total equity attributable to shareholders of ¥6,762,038,275.04, up from ¥6,512,959,205.55, a growth of approximately 3.8%[19]